| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 35 | 2024 | 111 | 8.560 |
Why?
|
| Phenylthiohydantoin | 21 | 2025 | 48 | 3.630 |
Why?
|
| Prostatic Neoplasms | 31 | 2025 | 1798 | 3.210 |
Why?
|
| Benzamides | 21 | 2025 | 248 | 3.140 |
Why?
|
| Nitriles | 21 | 2025 | 157 | 2.790 |
Why?
|
| Androstenes | 13 | 2024 | 39 | 2.690 |
Why?
|
| Receptors, Glucocorticoid | 7 | 2024 | 144 | 2.320 |
Why?
|
| Receptors, Androgen | 14 | 2024 | 120 | 1.960 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 2605 | 1.330 |
Why?
|
| Androgen Antagonists | 14 | 2025 | 144 | 1.310 |
Why?
|
| Neoplasm Metastasis | 21 | 2024 | 1079 | 1.200 |
Why?
|
| Neoplastic Cells, Circulating | 6 | 2024 | 73 | 1.180 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 2385 | 1.070 |
Why?
|
| Androgen Receptor Antagonists | 6 | 2024 | 20 | 0.900 |
Why?
|
| Male | 67 | 2025 | 45686 | 0.830 |
Why?
|
| Food-Drug Interactions | 2 | 2014 | 19 | 0.800 |
Why?
|
| Sulfonamides | 5 | 2019 | 337 | 0.790 |
Why?
|
| Prostate-Specific Antigen | 8 | 2025 | 346 | 0.710 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 611 | 0.700 |
Why?
|
| Aged, 80 and over | 27 | 2025 | 7215 | 0.680 |
Why?
|
| Testosterone | 4 | 2021 | 276 | 0.620 |
Why?
|
| Humans | 74 | 2025 | 95802 | 0.600 |
Why?
|
| Aged | 39 | 2025 | 20848 | 0.590 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 224 | 0.590 |
Why?
|
| Orchiectomy | 4 | 2018 | 63 | 0.590 |
Why?
|
| Quality of Life | 6 | 2024 | 1816 | 0.580 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 382 | 0.570 |
Why?
|
| Pyrimidines | 5 | 2019 | 386 | 0.550 |
Why?
|
| Ascites | 1 | 2018 | 57 | 0.550 |
Why?
|
| Food | 1 | 2018 | 93 | 0.530 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 1346 | 0.530 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 303 | 0.520 |
Why?
|
| Prospective Studies | 12 | 2024 | 4664 | 0.510 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 69 | 0.500 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 188 | 0.490 |
Why?
|
| Middle Aged | 34 | 2025 | 28208 | 0.490 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2023 | 23 | 0.480 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 2777 | 0.480 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 644 | 0.430 |
Why?
|
| Disease Progression | 7 | 2020 | 1559 | 0.430 |
Why?
|
| Prednisone | 4 | 2022 | 252 | 0.430 |
Why?
|
| Patient Safety | 4 | 2019 | 223 | 0.410 |
Why?
|
| Immediate-Early Proteins | 2 | 2014 | 164 | 0.410 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 117 | 0.410 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 65 | 0.410 |
Why?
|
| Dietary Fats | 1 | 2014 | 137 | 0.400 |
Why?
|
| Treatment Outcome | 18 | 2024 | 9167 | 0.400 |
Why?
|
| Food Labeling | 1 | 2012 | 8 | 0.390 |
Why?
|
| Indoles | 1 | 2014 | 317 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1021 | 0.360 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2024 | 106 | 0.360 |
Why?
|
| Neoplasms | 6 | 2023 | 3242 | 0.350 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 69 | 0.340 |
Why?
|
| Melanoma | 1 | 2014 | 495 | 0.310 |
Why?
|
| Mice, Nude | 4 | 2017 | 830 | 0.300 |
Why?
|
| Signal Transduction | 9 | 2024 | 3581 | 0.300 |
Why?
|
| Cell Survival | 3 | 2017 | 1029 | 0.290 |
Why?
|
| Mifepristone | 2 | 2022 | 51 | 0.280 |
Why?
|
| Hormones | 3 | 2022 | 144 | 0.260 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 87 | 0.260 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 3155 | 0.240 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1670 | 0.240 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 563 | 0.230 |
Why?
|
| Androgens | 3 | 2023 | 177 | 0.220 |
Why?
|
| Neutropenia | 2 | 2023 | 211 | 0.220 |
Why?
|
| Phthalazines | 1 | 2024 | 53 | 0.210 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.210 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.200 |
Why?
|
| CDC2 Protein Kinase | 1 | 2023 | 47 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1192 | 0.200 |
Why?
|
| Radium | 1 | 2023 | 7 | 0.200 |
Why?
|
| Piperazines | 1 | 2024 | 296 | 0.190 |
Why?
|
| Capecitabine | 2 | 2024 | 99 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 125 | 0.190 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 557 | 0.190 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 1194 | 0.180 |
Why?
|
| Dehydroepiandrosterone | 2 | 2020 | 50 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 245 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2024 | 263 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 154 | 0.180 |
Why?
|
| Frailty | 1 | 2023 | 94 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2017 | 1753 | 0.170 |
Why?
|
| Abiraterone Acetate | 2 | 2018 | 11 | 0.170 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 23 | 0.170 |
Why?
|
| Castration | 2 | 2012 | 36 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 412 | 0.160 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2020 | 18 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2021 | 101 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2024 | 369 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1965 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2025 | 703 | 0.160 |
Why?
|
| Dietary Supplements | 1 | 2021 | 134 | 0.160 |
Why?
|
| Double-Blind Method | 5 | 2025 | 1791 | 0.160 |
Why?
|
| Organic Chemicals | 1 | 2019 | 37 | 0.150 |
Why?
|
| Boronic Acids | 1 | 2019 | 55 | 0.150 |
Why?
|
| Oxidoreductases | 1 | 2019 | 115 | 0.150 |
Why?
|
| Pain | 1 | 2022 | 426 | 0.150 |
Why?
|
| Animals | 8 | 2024 | 28889 | 0.150 |
Why?
|
| Taxoids | 2 | 2016 | 129 | 0.150 |
Why?
|
| Pyridones | 1 | 2019 | 68 | 0.150 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 15 | 0.140 |
Why?
|
| United States | 6 | 2020 | 7764 | 0.140 |
Why?
|
| Azepines | 1 | 2018 | 28 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 16 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2019 | 131 | 0.140 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 40 | 0.140 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2018 | 20 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 40 | 0.140 |
Why?
|
| Singapore | 1 | 2018 | 15 | 0.140 |
Why?
|
| Recurrence | 2 | 2019 | 1211 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 316 | 0.140 |
Why?
|
| Quinolines | 1 | 2018 | 89 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 286 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 78 | 0.130 |
Why?
|
| Fasting | 1 | 2018 | 164 | 0.130 |
Why?
|
| Adult | 13 | 2021 | 28578 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 104 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 655 | 0.130 |
Why?
|
| Mice | 6 | 2024 | 12537 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 245 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2021 | 816 | 0.130 |
Why?
|
| Prostatectomy | 1 | 2020 | 480 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 200 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 449 | 0.130 |
Why?
|
| Quinolones | 1 | 2016 | 57 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2024 | 1739 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 528 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 327 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 132 | 0.120 |
Why?
|
| Benzodioxoles | 1 | 2015 | 15 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 897 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 366 | 0.110 |
Why?
|
| Female | 10 | 2021 | 49872 | 0.110 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2014 | 1 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 270 | 0.110 |
Why?
|
| Quinazolines | 1 | 2015 | 216 | 0.110 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 155 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 299 | 0.110 |
Why?
|
| Benzoates | 1 | 2014 | 33 | 0.100 |
Why?
|
| Proteins | 1 | 2019 | 816 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 667 | 0.100 |
Why?
|
| Prognosis | 3 | 2018 | 3990 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2014 | 91 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2014 | 279 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 103 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2014 | 218 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 726 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 385 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 294 | 0.090 |
Why?
|
| Hospitalization | 1 | 2018 | 943 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 422 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 443 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1192 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2018 | 1730 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2014 | 350 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2018 | 766 | 0.090 |
Why?
|
| Indazoles | 3 | 2019 | 61 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2014 | 706 | 0.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 37 | 0.090 |
Why?
|
| G1 Phase | 1 | 2011 | 66 | 0.090 |
Why?
|
| Decision Making | 2 | 2014 | 694 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2014 | 1540 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 157 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1463 | 0.080 |
Why?
|
| Survival Rate | 3 | 2019 | 1971 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2011 | 322 | 0.080 |
Why?
|
| Chicago | 3 | 2025 | 1505 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2013 | 447 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1805 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 484 | 0.070 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 61 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2019 | 297 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2009 | 38 | 0.070 |
Why?
|
| Prostate | 3 | 2018 | 423 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 630 | 0.070 |
Why?
|
| Nausea | 2 | 2019 | 181 | 0.070 |
Why?
|
| Geriatric Assessment | 2 | 2023 | 192 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1827 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 2061 | 0.060 |
Why?
|
| Age Factors | 2 | 2023 | 1957 | 0.060 |
Why?
|
| Rats | 1 | 2011 | 4154 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2024 | 2480 | 0.050 |
Why?
|
| CpG Islands | 1 | 2025 | 169 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3904 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3639 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 64 | 0.050 |
Why?
|
| Leuprolide | 1 | 2024 | 36 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1011 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2023 | 454 | 0.050 |
Why?
|
| Scandium | 1 | 2023 | 4 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2882 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2023 | 43 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10273 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 3106 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2024 | 2089 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2024 | 394 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 175 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 216 | 0.050 |
Why?
|
| Cystectomy | 1 | 2024 | 114 | 0.050 |
Why?
|
| DNA Repair | 1 | 2024 | 376 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2012 | 15 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 2042 | 0.050 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 16 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 33 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 579 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 49 | 0.040 |
Why?
|
| Thyrotoxicosis | 1 | 2001 | 18 | 0.040 |
Why?
|
| Purines | 1 | 2022 | 97 | 0.040 |
Why?
|
| Tissue Extracts | 1 | 2021 | 25 | 0.040 |
Why?
|
| Cisplatin | 1 | 2024 | 599 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2022 | 51 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2021 | 47 | 0.040 |
Why?
|
| Keratins | 1 | 2021 | 63 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2021 | 51 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 5561 | 0.040 |
Why?
|
| Neurosecretory Systems | 1 | 2021 | 37 | 0.040 |
Why?
|
| Glycolysis | 1 | 2022 | 191 | 0.040 |
Why?
|
| Cell Count | 1 | 2021 | 202 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 43 | 0.040 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2001 | 118 | 0.040 |
Why?
|
| Prescription Drugs | 1 | 2021 | 39 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2021 | 245 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 555 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 397 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 604 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 328 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1006 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 173 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2021 | 465 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 301 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 517 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 296 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 355 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2386 | 0.040 |
Why?
|
| Bradycardia | 1 | 2018 | 45 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 810 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2019 | 296 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 857 | 0.030 |
Why?
|
| Mitochondria | 1 | 2022 | 621 | 0.030 |
Why?
|
| Vomiting | 1 | 2019 | 201 | 0.030 |
Why?
|
| Kinetics | 1 | 2020 | 1561 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 357 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 883 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 5961 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1349 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 750 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 769 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 686 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Ketoconazole | 1 | 2014 | 24 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 547 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 106 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2014 | 147 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 139 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2575 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1560 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1425 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 154 | 0.020 |
Why?
|
| Cause of Death | 1 | 2014 | 278 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 796 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 4374 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 216 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2859 | 0.020 |
Why?
|
| Kallikreins | 1 | 2012 | 46 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 87 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 182 | 0.020 |
Why?
|
| United States Department of Defense | 1 | 2011 | 4 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 740 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 900 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 170 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 386 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 1096 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 154 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 185 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 181 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 815 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1267 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 239 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 649 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 378 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 710 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 705 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 708 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 933 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1878 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 126 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 569 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 264 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 7026 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 701 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 9873 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 516 | 0.020 |
Why?
|
| Homeostasis | 1 | 2008 | 467 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1166 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2001 | 72 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 2001 | 124 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 977 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2001 | 352 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 747 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 3237 | 0.010 |
Why?
|